The SORAMIC Study
SORAMIC is the first large randomised controlled trial (RCT) to compare the efficacy and safety of combining sorafenib and SIR-Spheres® Y-90 resin microspheres versus sorafenib alone in the treatment of HCC in the palliative cohort. Patients with HCC who took part in the palliative cohort of the SORAMIC study were not eligible for resection or ablation, and were not ideal candidates for transarterial chemoembolisation (TACE).
The primary endpoint of the palliative arm of the SORAMIC study is Overall Survival (OS). Secondary endpoints include Safety and OS for patients with and without portal vein thrombosis.
Results of the SORAMIC study are expected in 2018.